In the present work, we explored the feasibility of using palbociclib as a low-molecular weight analogue of TGF-β1 to induce senescence in hepatoma cells and to study how the pre-senescent status of the cells affects HCV replication and the efficacy of representative anti-HCV agents. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.